Introduction: The World health organization (WHO) has defined stroke as “rapidly developing clinical signs of focal (or global) cerebral function, with symptoms lasting 24 hours or longer or leading to death, with no apparent cause other than vascular region.”

Material and Methods: This case-control study was conducted on 145 individuals (58 ischemic strokes and 29 haemorrhagic strokes as the case groups; 58 healthy individuals as the control group).

Diagnosis: The diagnosis of stroke was based on history, clinical examination and brain CT scan was used to confirm and classify as ischemic or haemorrhagic stroke cases.

Results: A total of 87 cases of stroke (58 ischemic stroke, 29 haemorrhagic strokes, and 58 healthy individuals as the control group) were identified during the study follow-up. Glutathione peroxides (GPX) levels are reduced significantly in Ischemic Stroke Patients (ISPs) and haemorrhagic stroke Patients (HSPs) equated with control subjects (p<0.001). Extreme decrease in GPX is seen in ISPs than HSPs (p<0.001).

Conclusion: Finally, positive direct relationship was seen in MDA along with infarct size. So, it could consider as a biomarker for diagnosis of stroke. This could be valued for improving the dose frequency for improvement of patient health. From these studies, we can conclude that antioxidant defence is reduced in ischemic stroke patients as a significance of inclined oxidative stress.

 

Abbreviations: MDA-Malondialdehyde; GPX- Glutathione peroxides; ISPs-Ischemic Stroke Patients; HSPs-Haemorrhagic stroke Patients